Diversity, Equity and Inclusion:
Measuring our progress in our DE&I journey
Inspiring a culture of diversity, equity, and inclusion
Commitment to Diversity in Clinical Trials
We developed and implemented new guidance on "Enhancing Diversity Equity and Inclusion in our Clinical Trials." Our clinical teams use this to define diversity in a clinical trial and key areas to consider when designing and operationalizing a clinical trial, such as protocol design, country and site considerations, leveraging different data sources and patient advocacy, and community engagement ultimately to bring our clinical trials closer to reality.
We are finding new ways to connect to unique and diverse patient populations through our technological and data driven approaches by identifying best practices around scientific rigor, informing innovation, and addressing health inequities.
We are exploring and deploying tactics to diversify clinical trials.
Reaching carbon neutrality by 2030
Our commitment to becoming carbon neutral by 2030 for the operations we directly control will be achieved through two mechanisms:
• 80% of our time, effort and money will be invested in reducing our greenhouse gas (GHG) emissions by changing the way we operate
• 20% will be dedicated to offsetting the short-term impact we cannot avoid via compensation programs.
Taking concrete action to reduce GHG emissions we don’t directly control
The indirect impact created by the activities of our goods and services suppliers on behalf of UCB represents a significant proportion of our CO2e emissions.
In recent years, UCB has been working with suppliers and supporting them to shift towards a low-carbon economy. UCB’s CO2e indirect impact baseline, which was fully calculated in 2021, sets a clear vision of UCB’s suppliers and Contract Manufacturing Organizations’ (CMOs) CO2 emissions as well as their level of maturity in the low carbon economy.
In this regard, we are now requesting CMOs and other partners to join us on our quest to define ambitious climate targets with an aim to have 60% of the emissions created by our suppliers covered by SBTi-inspired goals.
Eco-design for drug development
UCB is paying close attention to the environmental impacts of chemical manufacturing, and more specifically, working on the eco-design of our medicine production processes.
To evaluate our efforts in this area, UCB chose in 2019 to adopt the Global Warming Potential (GWP) metric developed by the American Chemical Society’s (ACS) Green Chemical Institute (GCI). In 2020, the business process to set up ambitious targets for every new synthetic molecule was put in place. At the end of 2021, the first-year review took place, showing that UCB had already made considerable progress towards reaching its target.
Creating greener workspaces and reducing waste
UCB is embracing new workplace initiatives to support a greener UCB. One of these initiatives is our new Atlanta Warehouse (inspace) that features a sustainable kitchen focused on decreasing paper and plastic consumption by incorporating reusable/washable plates, silverware and glasses, and promoting a farm-to-table approach to in-office dining. Nearly 92% of waste from the first phase of demolition at the Warehouse was reused throughout the Atlanta inspace. It also features two 8,000-gallon rainwater collection cisterns that will assist in reducing our water consumption.
Access & Affordability:
Sustainable Access and Pricing Transparency
This report includes:
• How we deliver affordable access and account for value, including our pricing
• Our actions aimed at sustainable access in the U.S. healthcare system
• Policy reform opportunities to build a sustainable system together
Improving access for underserved populations
Our goal is that by 2030, all patients who need our medicines in countries where we operate have access to them. UCB recently created a new managed access program called Access+. Our approach is to provide access to our treatments through a standard mechanism in place for receipt, review, decision, management, and closure of unsolicited requests and activities related to supplying investigational products or products approved by at least one major regulatory body.
In the U.S., we’re looking to build on our health equity work by developing new social business approaches that stand up to healthcare disparities seen in the communities around us. While we’re in the early stages of developing a blueprint, this will include leveraging an “Innovation Hub” model to incubate new approaches and engaging with underserved and marginalized communities to offer solutions that use a human-centered design approach.